On a segmental basis, revenues from pharmaceuticals rose marginally by 0.08% to Rs 279.56 crore in Q2 FY22 as against Rs 279.31 crore in Q2 FY21. Revenues from Crop Protection grew 104.62% to Rs 189.50 crore in Q2 September 2021 as compared to Rs 92.61 crore in Q2 September 2020.
Hikal is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharmaceutical ingredients (APIs) and contract research activities.
Powered by Capital Market - Live News
FOR GRIEVANCE MAIL TO invgrieviss@iseindia.com
BSE EQUITIES : INB011077733 | NSE F&O EQUITIES : INF231077737 | NSE CASH MARKET : INB231077737 | NSE CURRENCY DERIVATIVES : INE231077737 | MCX-SX : INE261077737
ISS Enterprise Limited [Erstwhile: ISE Securities & Services Limited], a wholly owned subsidiary of Inter-connected Stock Exchange of India Ltd. (ISE)
© 2013 ISS Enterprise Limited [Erstwhile: ISE Securities & Services Limited]. All rights reserved.
Designed, developed & powered by C-MOTS Infotech (ISO 9001:2008 certified)
